Neidig Brent, Chief Operating Officer and Managing Director of China at USANA Health Sciences, Inc. (USNA), has demonstrated a consistent pattern of selling activity over the past several years, as evidenced by SEC Form 4 filings. Since 2024, Brent has executed 29 transactions, all involving USNA shares, with a total sell value of $751,563.64 and no recorded purchases. This activity reflects a clear selling bias, with no indication of recent acquisitions of company stock. Notably, Brent’s most recent sales occurred on March 6, 2024, and March 12, 2025, with values of $179,066.19 and $153,387.20, respectively. These transactions represent the largest single sales in the dataset.
In addition to outright sales, Brent has engaged in multiple transactions coded as "F" (indicating the exercise of derivative securities, such as options) and "M" (representing the conversion of derivative securities). These filings, particularly concentrated in February of each year, suggest a recurring pattern tied to the vesting or expiration of equity awards. For example, on February 8, 2024, Brent exercised options valued at $32,950.80, followed by a similar transaction on February 7, 2024, worth $30,919.62. These filings, while not direct sales, contribute to the overall trend of reducing equity exposure. Brent’s trading activity underscores a sustained focus on liquidating USNA holdings, with no deviation toward accumulation in recent years.
AI-assisted summary